Natural killer (NK) and T cell-associated surface marker expression following allogeneic and autologous bone marrow transplantation (BMT).
Natural killer (NK) and T cell development was studied after allogeneic and autologous BMT. We determined the phenotypic expression and lytic ability of these subpopulations after BMT. Following T cell-depleted (TCD) BMT, the number of CD16+ and CD56+ cells peaked at 39 and 46 days, respectively, and constituted the majority of peripheral blood lymphocytes (PBL). Coexpression of CD3 and CD16 was <10% up to 14.5 weeks after transplant. Following allogeneic non-T cell-depleted (NTCD) BMT, the number of CD16+ and CD56+ cells peaked at 6 weeks. CD3 expression was normal (70%-80%), % CD8+ cells was high (40%), and % CD4+ cells was low (20%). Following autologous BMT (ABMT), % CD3+ T cells was 80%, of which 70% expressed the CD8 marker. In contrast, CD4 expression was low (20%). CD16+ cells appeared 2.5-3 weeks after ABMT but with low frequency (20%), at which point 20%-30% of the CD3+ cells coexpressed CD16. A positive correlation was found between CD16 expression and cytotoxic capability. In conclusion, a marked difference was observed in NK and T cell-associated markers following TCD BMT, NTCD BMT, and ABMT. Following NTCD or ABMT, but not TCD BMT, a high percentage of cells co-express CD16 and CD3, which may indicate the possibility of a common NK and T cell progenitor.
Nagler
A
A
Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel.
Rabinowitz
R
R
Rosengolts-Rat
J
J
Condiotti
R
R
Schlesinger
M
M
D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000097:blood / Q000378:metabolism*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D019002:CD56 Antigen / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D007694:Killer Cells, Natural / Q000166:cytology* / Q000276:immunology; D008212:Lymphocyte Depletion; D016131:Lymphocyte Subsets / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000097:blood; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000097:blood; D017452:Receptors, IgG / Q000097:blood; D013601:T-Lymphocytes / Q000166:cytology* / Q000276:immunology; D013997:Time Factors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
D015703:Antigens, CD; D019002:CD56 Antigen; D016693:Receptors, Antigen, T-Cell, alpha-beta; D016692:Receptors, Antigen, T-Cell, gamma-delta; D017452:Receptors, IgG